HUBUC Launches P1, a global card issuing and processing engine, becoming a Mastercard Network Enablement Partner
15.2.2023 10:07:00 EET | Business Wire | Press release
Leading fintech company HUBUC announces the immediate availability of its revolutionary issuing processor, a Mastercard-certified platform that makes card issuing easier than ever.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230213005527/en/
HUBUC Founders, Ignacio Javierre and Hasan Nawaz (Photo: Business Wire)
The platform has global scalability and plug-and-play connectivity at its core, allowing financial institutions and fintechs to enhance their customer experiences and deploy disruptive payment card use cases in a matter of weeks.
HUBUC decided to build P1, a new issuing processor in-house when existing ones proved to be running on legacy technology from the 1960's and provided outdated functionalities.
HUBUC's commitment with P1 is to bring lightning-fast performance, lean implementation and microservices architecture that allows scalability and innovation for years to come.
The cloud-based platform has key capabilities such as card-level spending controls, regulatory issuer reporting, cloud processing for scalability and comes with a stellar developer experience with Public Sandbox and OpenAPI specification.
Additionally, the platform offers strong customer authentication for enhanced security against fraud, and is GDPR, PSD2 and PCI DSS 3.2 Level 1 compliant.
The platform’s powerful issuing processor is the ultimate infrastructure to innovate with a Mastercard product and generate new revenue streams, improve unit economics and become a leading company in any sector.
P1 customers like Coverflex are an example of how to leverage HUBUC services. Coverflex’s solution allows a company to design more bespoke employee compensation, such as health insurance, meal allowance, fringe benefits and discounts, by aggregating multiple providers. This year Coverflex recently raised €15 million Series A, to keep increasing their existing customer base of 3,600+ companies, including Santander, Natixis, OysterHR, Bolt, Emma, Revolut and Smartex.
In a statement, Coverflex CEO Miguel Amaro said: “At Coverflex, we are dedicated to providing cutting-edge employee benefits via a smart card to our clients in Europe. Our focus on increasing the unit economics and scalability of our card product has been a top priority, and we are thrilled to announce that our partnership with HUBUC has enabled us to achieve this goal. Working with industry leaders like Ignacio and Hasan has been a truly enlightening experience, allowing us to expand our knowledge and understanding of the payments world. This collaboration has allowed us to significantly enhance our proposition to our clients, delivering increased efficiency and a better user experience for our cardholders.”
HUBUC's leadership team has been innovating in the fintech industry for years and brings experience building financial infrastructure across Europe to scale it globally.
HUBUC is backed by some of the best venture capitalists and operators in the industry, such as Y Combinator, Jeffrey Katzenberg (Managing Partner at WndrCo, Former Chairman Walt Disney Studios and DreamWorks Animations), Runa Capital, Village Global, Eric Yuan (Zoom), John Lilly (Mozilla), Immad Akhund (Mercury), John Bautista (Orrick), Charles Delingpole (ComplyAdvantage) among others.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230213005527/en/
Contact information
HUBUC Inc.
press@hubuc.com | Ignacio Javierre
https://www.hubuc.com/about-us
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom